The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weinstein, M. C., O'Brien, B., Hornberger, J., Jackson, J., Johannesson, M., McCabe, C., & Luce, B. R. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.00234.x · Cited by 1,172
Ramsey, S., Willke, R., Briggs, A., Brown, R., Buxton, M., Chawla, A., Cook, J., Glick, H., Liljas, B., Petitti, D., et al. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.00045.x · Cited by 720
Simon, G. E. (1996) · JAMA · doi:10.1001/jama.275.24.1897 · Cited by 294
Developing Guidance for Budget Impact Analysis
Trueman, P., Drummond, M., & Hutton, J. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119060-00001 · Cited by 228
Self-citationDrummond, M., Brown, R. E., Fendrick, A. M., Fullerton, P., Neumann, P. J., Taylor, R. S., & Barbieri, M. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.64245.x · Cited by 131
The Members of the Italian Group for Pharmacoeconomic Studies, Capri, S., Ceci, A., Terranova, L., Merlo, D. F., & Mantovani, L. G. (2001) · Drug Information Journal · doi:10.1177/009286150103500122 · Cited by 123
Budget impact analysis: review of the state of the art
Mauskopf, J., Earnshaw, S., & Mullins, C. D. (2005) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.5.1.65 · Cited by 82
Self-citationTonelli, M. A., Winkelmayer, W. C., Jindal, K. K., Owen, W. F., & Manns, B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00079.x · Cited by 78
Prevalence-Based Economic Evaluation
Mauskopf, J. (1998) · Value in Health · doi:10.1046/j.1524-4733.1998.140251.x · Cited by 77
Self-citationSzende, Á., Mogyorósy, Z., Muszbek, N., Nagy, J., Pallos, G., & Dózsa, C. (2002) · The European Journal of Health Economics · doi:10.1007/s10198-002-0109-6 · Cited by 60
Research works printed but not linked: 15
- Koopmanshap, 2001, The drug budget silo mentality: the Dutch case, Value Health, 6, S46
- Annemans, 2002, Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium, Pharm World Service, 24, 5, 10.1023/A:1014896830042 · doi:10.1023/a:1014896830042
- Orlewska, 2004, Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries, Value Health, 7, 1, 10.1111/j.1524-4733.2004.71257.x · doi:10.1111/j.1524-4733.2004.71257.x
- Mullins, 2000, Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy, Manag Care Pharm, 9, 150, 10.18553/jmcp.2003.9.2.150 · doi:10.18553/jmcp.2003.9.2.150
- Grima, 2002, Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture, P&T, 27, 448
- Mason, 1999, Population-based and opportunistic screening and eradication of Helicobacter pylori, Int J Tech Assess, 15, 649, 10.1017/S0266462399015445 · doi:10.1017/s0266462399015445
- Mauskopf, 2000, Meeting the NICE requirements: a Markov Model approach, Value Health, 3, 287, 10.1046/j.1524-4733.2000.34006.x · doi:10.1046/j.1524-4733.2000.34006.x
- Zabinski, 2001, An economic model for determining the costs and consequences of using various treatment alternatives for the management for arthritis in Canada, Pharmacoeconomics, 19, S49, 10.2165/00019053-200119001-00004 · doi:10.2165/00019053-200119001-00004
- Orlewska, 2002, The cost-effectiveness of alternative therapeutic strategies for management of chronic hepatitis B in Poland, Value Health, 5, 404, 10.1046/J.1524-4733.2002.55147.x · doi:10.1046/j.1524-4733.2002.55147.x
- Nuijten, 2002, Combining a budgetary impact analysis and a cost-effectiveness analysis using decision analytic modeling techniques, Pharmacoeconomics, 20, 855, 10.2165/00019053-200220120-00006 · doi:10.2165/00019053-200220120-00006
- Tavakoli, 2003, Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam, Pharmacoeoconomics, 23, 443, 10.2165/00019053-200321060-00007 · doi:10.2165/00019053-200321060-00007
- Dykstra, 2003, ESRD managed care demonstration: financial implications, Health Care Financ Rev, 24, 59
- Bigal, 2003, Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care, Headache, 43, 742, 10.1046/j.1526-4610.2003.03132.x · doi:10.1046/j.1526-4610.2003.03132.x
- Casciano, 2003, Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails, Manag Care, 12, 47
- Brosa, 2005, Principios, métodos y aplicaciones del análisis del impacto presupuestario en sanidad, Pharmacoeconomics Spanish Research Articles, 2, 65, 10.1007/BF03320900 · doi:10.1007/bf03320900
Cited by
Bridges, J. F. P., Hauber, A. B., Marshall, D., Lloyd, A., Prosser, L. A., Regier, D. A., Johnson, F. R., & Mauskopf, J. (2011) · Value in Health · doi:10.1016/j.jval.2010.11.013 · Cited by 2,029
Self-citationA tutorial on sensitivity analyses in clinical trials: the what, why, when and how
Thabane, L., Mbuagbaw, L., Zhang, S., Samaan, Z., Marcucci, M., Ye, C., Thabane, M., Giangregorio, L., Dennis, B., Kosa, D., et al. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-92 · Cited by 893
Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Pashayan, N., Antoniou, A. C., Ivanus, U., Esserman, L. J., Easton, D. F., French, D., Sroczynski, G., Hall, P., Cuzick, J., Evans, D. G., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0388-9 · Cited by 438
Baker, T. B., McFall, R. M., & Shoham, V. (2008) · Psychological Science in the Public Interest · doi:10.1111/j.1539-6053.2009.01036.x · Cited by 342
(2011) · PubMed · Cited by 321
Metadata
- Authors
- Mauskopf, J. A., Sullivan, S. D., Annemans, L., Caro, J., Mullins, C. D., Nuijten, M., Orlewska, E., Watkins, J., & Trueman, P.
- Venue
- Value in Health
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 10
- Issue
- 5
- Pages
- 336-347
- ISSN
- 1098-3015 (ISSN-L)
- OpenAlex
- W2126502186
- Cited by
- 750
- References
- 19
- FWCI
- 61.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2145 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. https://app.cochat.ai/papers/10.1111/j.1524-4733.2007.00187.x
- The paper
- Mauskopf, J. A., Sullivan, S. D., Annemans, L., Caro, J., Mullins, C. D., Nuijten, M., Orlewska, E., Watkins, J., & Trueman, P. (2007). Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. Value in Health. https://doi.org/10.1111/j.1524-4733.2007.00187.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.